TTD | Drug: D0W9ZY

Drug General Information
Drug ID	D0W9ZY
Former ID	DIB009367
Drug Name	CE-326597
Drug Type	Small molecular drug
Indication	Obesity [ICD9: 278; ICD10:E66]		Discontinued in Phase 2	[522138]
Company	Pfizer Inc
Structure		Download 2D MOL 3D MOL
Formula	C37H34N6O2
Canonical SMILES	CC(C)N(Cc1ccccc1)C(=O)CN2C(=O)[C@@H](Cc3c[nH]c4ccccc34)<br />c5nnc(c6ccccc6)n5c7ccccc27
InChI	1S/C37H34N6O2/c1-25(2)41(23-26-13-5-3-6-14-26)34(44)24-42-32-19-11-12-20-33(32)43-35(27-15-7-4-8-16-27)39-40-36(43)30(37(42)45)21-28-22-38-31-18-10-9-17-29(28)31/h3-20,22,25,30,38H,21,23-24H2,1-2H3/t30-/m0/s1
InChIKey	UBNMGTSDHSQBEL-PMERELPUSA-N
PubChem Compound ID	52949124
Target and Pathway
Target(s)	Cholecystokinin receptor type A	Target Info	Agonist	[544295]
KEGG Pathway	Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Insulin secretion
	Pancreatic secretion
Reactome	Peptide ligand-binding receptors
Reactome	G alpha (q) signalling events
WikiPathways	GPCRs, Class A Rhodopsin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 522138	ClinicalTrials.gov (NCT00542009) A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight. U.S. National Institutes of Health.
Ref 544295	Obesity Pharmacotherapy: Current Perspectives and Future Directions. Curr Cardiol Rev. 2013 February; 9(1): 33-54.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information